UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | | | I.R.S. Employer | | --- | --- | --- | | Commission File Number | Exact name of registrants as specified in their charters | Identification Number | | | 001-0 ...

Exhibit 99.1 "While sales volumes were impacted by external headwinds, our gross margins remained resilient, supported by disciplined cost management and operational efficiency. At the same time, we continued to invest in the product development and global reach that will drive long-term value for our customers. We also took deliberate steps to reinforce our financial position and preserve the resources needed to support innovation and service." Socket Mobile Reports Fourth Quarter 2025 and Full Year Result ...

Exhibit 99.1 Dream Finders Announces Fourth Quarter and Full Year 2025 Results Record Home Closings of 8,608 for Full Year Record Net Sales of 7,747, Up 15% for Full Year Fourth Quarter Net Sales of 1,756, Up 9% Jacksonville, FL. — February 23, 2026 — Dream Finders Homes, Inc. (the "Company", "Dream Finders Homes", "Dream Finders" or "DFH") (NYSE: DFH) announced its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Highlights (As Compared to Fourth Quarter 2 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-14010 Waters Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 34 Maple Street Mil ...

Market Opportunity and Growth - GeneDx has amassed one of the largest rare disease datasets globally, GeneDx Infinity, powered by data from over 2.5 million tests, including over 1 million exomes and genomes [26]. - In 2025, GeneDx added 30% more rare disease exomes and genomes to GeneDx Infinity than in the previous 24 years combined [26]. - The company aims to capture a nearly $25 billion market opportunity in pediatric and rare diseases and a nearly $20 billion market opportunity for adult diseases and disorders [30]. - GeneDx plans to expand its market presence in the pediatric outpatient setting, particularly among general pediatricians, and into the Neonatal Intensive Care Unit (NICU) [28]. - The company expects to achieve a mix of revenue from diagnostic tests, data solutions, newborn screening products, and interpretation services in the long term [37]. Technological Advancements - GeneDx has reduced sequencing costs significantly since inception and expects further declines in costs going forward [32]. - The company leverages AI tools, such as a machine learning-powered gene ranker, to improve the speed and accuracy of genomic data interpretation [26]. - The company is enhancing its offerings with AI technologies, including a partnership with Fabric Genomics for Next Generation Sequencing analysis [129]. Regulatory Compliance and Risks - The company is committed to maintaining compliance with extensive and frequently changing laws and regulations, including the Clinical Laboratory Improvement Amendments (CLIA) and state regulations [53]. - The company is currently offering laboratory developed tests (LDTs) and is monitoring potential changes in FDA oversight that could impose additional regulatory requirements [61]. - The company is subject to various federal and state healthcare fraud and abuse laws, including the Stark Law and Anti-Kickback Statute, which impose significant penalties for violations [71][72]. - The company must comply with HIPAA regulations to protect the privacy and security of protected health information (PHI), with potential penalties for non-compliance [80][84]. - The company is required to adhere to environmental and safety regulations regarding the handling and disposal of medical waste and hazardous materials [70]. Financial Performance and Challenges - The company has incurred net losses since inception, with an accumulated deficit of approximately $1.4 billion as of December 31, 2025 [131]. - The company’s operating results may fluctuate significantly, increasing stock price volatility and potential losses for shareholders [111]. - The company’s revenue growth rate may decline over time due to increasing competition and expansion into new fields, potentially impacting operating margins [177]. - The complexity of reimbursement and billing processes may lead to denied claims and substantial obligations to repay overpayments [106]. Human Capital and Management - The company employs nearly 1,300 individuals and emphasizes human capital management as critical to long-term success, investing in personal development and career growth [49]. - The company offers competitive compensation and benefits to attract and retain high-quality talent, including bonuses, equity awards, and comprehensive health benefits [51]. Strategic Partnerships and Acquisitions - The company completed the acquisition of Fabric Genomics in May 2025, which may enhance its product platform and market reach [188]. - The company aims to optimize its services to become the preferred solutions provider for biopharma companies, focusing on finding rare disease patients for clinical trials and supporting R&D for targeted therapies [41]. Market Competition and Positioning - Intense competition exists in the market, requiring the company to continuously innovate and provide useful products and services to remain competitive [119]. - The company’s success depends on the clinical acceptance of its tests, particularly exome and whole genome sequencing, which remains uncertain [113]. Data Privacy and Security - The company has established a trade secrecy program to protect its proprietary information and trade secrets, which are critical for maintaining its competitive position [46]. - The company has experienced security incidents involving unauthorized disclosure of PHI, which may require reporting to regulatory bodies and could impact reputation [208]. International Expansion and Risks - Approximately 1.5% of GeneDx's revenues are derived from referral sources outside of the United States, with plans to increase international revenue over time [38]. - The company is exploring international expansion, which could expose it to various business and regulatory risks [147]. Compliance with Consumer Protection Laws - The California Consumer Privacy Act (CCPA) imposes fines of up to $2,663 for each violation and $7,988 for intentional violations [89]. - By the end of 2025, sixteen other states will have consumer privacy laws in effect, potentially increasing compliance costs for the company [90]. Research and Development - The company must continue to invest heavily in research and development to enhance its diagnostics and health information technologies [119]. - The development and commercialization of new tests or services are complex and uncertain, requiring significant resources and time [166].

Financial Performance - In 2025, the company recorded a net loss attributable to common stockholders of $105.9 million, a decrease of $22.7 million from the previous year's loss of $128.6 million[548]. - Revenue for the year ended December 31, 2025 was $3.2 million, an increase of 15% from $2.9 million in 2024[552][553]. - CGI's gross profit for the year ended December 31, 2025 was $2.1 million, a 13% increase from $1.9 million in 2024[553]. - The provision for credit loss expense for the year ended December 31, 2025 was $10.3 million, related to expected credit loss from Red Sun[551]. - VRB Energy reported no revenue for the year ended December 31, 2025, a decrease from $0.1 million in 2024[554]. Exploration and Project Development - Exploration expenses for 2025 were $63.3 million, down from $130.9 million in 2024, with significant reductions in costs associated with the Santa Cruz Copper Project[549]. - The Santa Cruz Copper Project is projected to produce 1.4 million tonnes of copper cathode over a 23-year mine life, with an estimated after-tax Net Present Value of $1.4 billion at an 8% discount rate[530]. - The Preliminary Feasibility Study for the Santa Cruz Copper Project confirmed the economic viability of an underground mining operation, with an initial project capital estimated at $1.24 billion[530]. - Exploration expenditures for the Alacrán Project were $19.4 million in 2025, up from $14.8 million in 2024[550]. - The company completed the final three land acquisition payments totaling $39.3 million for the Santa Cruz Copper Project, satisfying all terms of the 2023 Purchase and Sale Agreement[531]. Financing Activities - The company completed a public offering in October 2025, issuing 11,500,000 shares at $15.00 per share for gross proceeds of approximately $172.5 million[526]. - The company received $81.5 million from the exercise of approximately 11.6 million Warrants at $7.00 per share in early 2026[568]. - Net cash provided by financing activities for the year ended December 31, 2025 was $214.7 million, mainly from $231.1 million raised in two public offerings[590]. - Mesa Cobre closed a $200.0 million senior secured multi-draw Bridge Facility to support the Santa Cruz Copper Project, which is currently undrawn[570]. - The company received a Letter of Interest from EXIM Bank for potential debt financing of up to $825 million for the Santa Cruz Copper Project, with a 15-year repayment term[571]. Cash and Liquidity - Cash and cash equivalents as of December 31, 2025 were $173.3 million, with a working capital balance of $126.3 million[567]. - As of December 31, 2025, consolidated cash balances totaled $173.3 million, with $170.2 million in the USA and $2.5 million in Canada[577]. - Net cash used in operating activities for the year ended December 31, 2025 was $89.2 million, primarily due to $61.1 million in exploration expenditures and $29.4 million in general and administrative costs[584]. - The net cash provided by investing activities for the year ended December 31, 2025 was $4.6 million, partly due to $9.7 million received from the sale of VRB China[587]. - As of December 31, 2025, total material cash obligations amounted to $38.8 million, including $33.7 million related to convertible debt[596]. Joint Ventures and Partnerships - The company has established a 50/50 joint venture with Saudi Arabian Mining Company to explore minerals on approximately 50,000 km of the Arabian Shield[521]. - Cordoba Minerals Corp. signed a definitive Framework Agreement for the sale of its remaining 50% interest in the Alacrán Copper Project for up to $128.0 million, with $88.0 million in cash at closing[533]. Tax and Regulatory Matters - The company recognizes uncertain income tax positions if they are more likely than not to be sustained, with no uncertain tax positions reported as of December 31, 2025[609]. - The realization of deferred tax assets is contingent on future taxable income generation, with valuation allowances provided for amounts not likely to be recognized[608]. - The company is subject to income tax laws in multiple jurisdictions, including the United States, Colombia, Canada, Australia, the Ivory Coast, and Peru[605]. Currency and Market Risks - The recoverable value of exploration mineral interests is subject to market factors such as commodity prices and geopolitical circumstances, which could materially impact financial statements[603]. - The appreciation of the Colombian Peso against the U.S. dollar was 15.2% for the year ended December 31, 2025, while the Canadian dollar appreciated by 4.7%[613]. - A 10% depreciation or appreciation of foreign currencies against the U.S. dollar would have resulted in an approximate $0.2 million decrease or increase in the company's net loss for the year ended December 31, 2025[613]. Debt Obligations - The balance of principal and interest on the convertible bond issued by VRB Energy was $33.7 million as of December 31, 2025, classified as a current liability[578]. - The company has a fixed-rate debt of $33.7 million with an interest rate of 8.0% per annum, while variable-rate debt is $nil[610]. - The company has an undrawn $200.0 million Bridge Facility related to the Santa Cruz Copper Project, which will have an interest rate of the secured overnight financing rate plus 5.0% when drawn[611].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ FORM 10-K _____________________________________ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ ...

Exhibit 99.1 Perpetua Resources Responsible Mining. Critical Resources. Clean Future. Investor Presentation – February 2026 N ASDAQ:PPTA TSX:PPTA FORWARD-LOOKING STATEMENTS nfromation and statements contained in this presentation thicace opt tipsvards colling information "or "for are booking station information" on "boners" with the meaning o lendataten and ine United States Rivate Securities Libandin Reform Act of 1975. Me yearst such as 'nex' "wpuld," "stould" "should" "while" "popula" "believe" "hyperd" ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-9328 ECOLAB INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________ FORM 10-K _______________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38000 _____________________________ ...